|
Sanofi R&D Spending Drops Almost 11 Percent in Q3 as Company Takes Generic Hits
Over the past quarter, Sanofi has reduced its R&D spending almost 11percent and has dropped two mid-stage projects acquired in its 2008 purchase of Fovea.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives